Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 272 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 272 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total value of $37,563.20. Following the transaction, the insider now owns 2,507 shares of the company’s stock, valued at $346,216.70. This represents a 9.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, December 17th, Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $135.00, for a total value of $147,285.00.

Neurocrine Biosciences Price Performance

Shares of NBIX stock traded up $0.24 during trading on Friday, reaching $138.10. The company’s stock had a trading volume of 745,425 shares, compared to its average volume of 799,262. The company has a market capitalization of $13.98 billion, a price-to-earnings ratio of 37.02 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The stock’s 50-day moving average price is $127.67 and its 200 day moving average price is $130.80.

Hedge Funds Weigh In On Neurocrine Biosciences

Several large investors have recently bought and sold shares of the business. Plato Investment Management Ltd grew its position in shares of Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after buying an additional 10,548 shares during the last quarter. Swiss National Bank boosted its stake in Neurocrine Biosciences by 1.4% in the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after acquiring an additional 4,100 shares in the last quarter. Tri Ri Asset Management Corp purchased a new position in shares of Neurocrine Biosciences during the third quarter worth about $3,236,000. KBC Group NV grew its holdings in shares of Neurocrine Biosciences by 78.3% during the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after purchasing an additional 8,332 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Neurocrine Biosciences by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock worth $2,238,000 after purchasing an additional 7,597 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NBIX. HC Wainwright reiterated a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. StockNews.com downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Raymond James reaffirmed an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $166.29.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.